Optimizing HIV Therapy for AIDS-Related Lymphoma Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares three antiretroviral strategies in adults with AIDS-related lymphoma who are undergoing anti-lymphoma treatment. Participants are randomized or selected to receive: oral ART alone, oral ART plus long-acting albuvirtide, or long-acting cabotegravir with rilpivirine. The goal is to see which approach maintains virological suppression, supports immune recovery, and has acceptable safety during lymphoma therapy. Outcomes include virological control, immune response, occurrences of virological failure or low-level viremia, and overall safety. The study is conducted at Shanghai Public Health Clinical Center under the lead sponsorship of the center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Age ≥18 years. Confirmed HIV infection. Histologically confirmed AIDS-related lymphoma. Receiving anti-lymphoma treatment. Able and willing to provide written informed consent.

Exclusion Criteria:

\- Expected survival less than 6 months. Severe concomitant malignancy or uncontrolled comorbidity. Refusal to receive antiretroviral therapy or lymphoma treatment. Contraindications to study medications. Inability to complete scheduled follow-up. Any condition considered unsuitable by the investigator.

Where it's running

• Shanghai Public Health Clinical Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Zhenyan Wang
• Email: wangzhenyan@shaphc.org
• Phone: +86021-37990333-3222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Expanding HIV-positive donor livers for HIV-positive recipients

  This study tests whether liver transplants from HIV-positive donors to HIV-positive recipients are safe regarding opportunistic infections and cancer.

  Recruiting at 2 sites National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 1 other locations · NCT07778459

• Colchicine to see if it reduces coronary artery inflammation in people with HIV

  This study tests whether low-dose colchicine can lower inflammation in the coronary arteries of people with HIV who are at high heart-disease risk, compared with a placebo.

  Recruiting at 2 sites Phase 2 Instituto de Investigación Hospital Universitario La Paz · Barcelona and 3 other locations · NCT07704164

• Darunavir/ritonavir plus lamivudine vs darunavir/ritonavir plus tenofovir alafenamide/emtricitabine in virologically suppressed adults with HIV

  This trial tests whether a two-drug regimen (darunavir/cobicistat plus lamivudine) works as well as a three-drug regimen (darunavir/cobicistat plus TAF/FTC) in adults with HIV who have stable viral suppression.

  Recruiting Phase 4 Instituto Mexicano del Seguro Social · Mexico City, Mexico City · NCT07678268

• Dental care for people living with HIV in Pays de la Loire

  This study looks at whether people living with HIV in Pays de la Loire need any special dental management based on their health data.

  Recruiting Nantes University Hospital · Nantes, Nantes · NCT07552038

• Cardiovascular health in children and young adults with chronic conditions

  This project will see if children and young adults (ages 6-25) with chronic health conditions show early signs of aging in large and small blood vessels using noninvasive imaging and clinical tests.

  Recruiting Semmelweis University · Budapest and 2 other locations · NCT07086989

• DTG/3TC versus BIC/TAF/FTC as first-line HIV treatment for people new to antiretrovirals

  This trial will test whether DTG/3TC gives similar viral control but less weight gain and metabolic side effects than BIC/TAF/FTC in adults newly starting HIV treatment.

  Recruiting Phase 4 Instituto Mexicano del Seguro Social · Mexico City, Azcapotzalco · NCT07031063

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.